Taysha Gene Therapies, Inc.

TSHA

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001806310

SEC filings (opens in a new tab)

In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Taysha Gene Therapies, Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024 All holders in Q3 2024

13F holders of TSHA: Q3 2024 compared with Q4 2024
Measure	Q3 2024	Of which not filed for Q4 2024	Q4 2024	Change
Holders	119	1	131	+13
Shares	157.0M	2.15M	167.5M	+12.6M (+8.2%)
Value	$315.5M	$4.32M	$289.8M	−$21.5M (−6.9%)

1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (28)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to TSHA in Q4 2024
Institution	Shares	Value	% of portfolio
Adage Capital Partners GP, L.L.C.	5,000,000	$8.65M	0.02%
Norges Bank	1,461,120	$2.53M	0.00%
B Group, Inc.	965,556	$1.67M	1.02%
Renaissance Technologies LLC	878,448	$1.52M	0.00%
DAFNA Capital Management LLC	522,500	$903.9K	0.23%
Rafferty Asset Management, LLC	252,257	$436.4K	0.00%
Millennium Management LLC	151,614	$262.3K	0.00%
Virtu Financial LLC	107,544	$186.0K	0.01%
Aquatic Capital Management LLC	78,246	$135.4K	0.00%
LPL Financial LLC	60,000	$103.8K	0.00%
Profund Advisors LLC	50,242	$86.9K	0.00%
Police & Firemen's Retirement System of New Jersey	45,678	$79.0K	0.00%
Engineers Gate Manager LP	35,808	$61.9K	0.00%
Verition Fund Management LLC	34,098	$59.0K	0.00%
First Manhattan Co	28,500	$49.3K	0.00%
BNP Paribas Arbitrage, SA	23,644	$40.9K	0.00%
Ameriprise Financial Inc	22,993	$39.8K	0.00%
Axq Capital, LP	22,432	$38.8K	0.02%
E Fund Management Co., Ltd.	17,844	$30.9K	0.00%
CIBC World Markets Corp	16,405	$28.4K	0.00%
Ground Swell Capital, LLC	14,660	$25.4K	0.06%
Two Sigma Investments, LP	12,300	$21.3K	0.00%
Skopos Labs, Inc.	4,500	$7.79K	0.00%
GF Fund Management Co. Ltd.	4,303	$7.44K	0.00%
CoreCap Advisors, LLC	380	$657	0.00%
Rothschild Investment LLC	130	$225	0.00%
R Squared Ltd	130	$225	0.00%
SBI Securities Co., Ltd.	80	$138	0.00%

Sold out (15)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.

Institutions that sold out of TSHA in Q4 2024
Institution	Shares, Q3 2024	Value, Q3 2024
Schonfeld Strategic Advisors LLC	843,200	$1.69M
Qube Research & Technologies Ltd	352,684	$708.9K
Gsa Capital Partners LLP	233,560	$469.0K
Franklin Resources Inc	100,795	$200.6K
Jefferies Financial Group Inc.	73,857	$148.5K
ExodusPoint Capital Management, LP	68,264	$137.0K
SEI Investments Co	39,188	$78.8K
Simplex Trading, LLC	38,813	$78.0K
Nebula Research & Development LLC	21,737	$43.7K
Aigen Investment Management, LP	11,189	$22.5K
Oliver Lagore Vanvalin Investment Group	2,800	$5.63K
Global Retirement Partners, LLC	1,006	$2.02K
Clear Street Markets LLC	424	$1.00K
Riggs Asset Managment Co. Inc.	198	$398
International Assets Investment Management, LLC	4,020	–

Not filed for Q4 2024 yet (1)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding TSHA in Q3 2024 that haven't filed for Q4 2024
Institution	Shares, Q3 2024	Value, Q3 2024
Ghost Tree Capital, LLC	2,150,000	$4.32M